Abstract:Monoclonal antibodies (mAbs) are potent antiviral therapeutics that offer advantages, including post-exposure protection and protection for immunocompromised individuals. They can be modified to express antigen-specific paratopes in mono-specific, bi-specific, and multi-specific formats. Most available mAbs are approved as cancer and auto-immune medications. However, the utility of antiviral mAbs has been underscored by their successful deployment against many viruses, such as Ebola virus, human respiratory syncytial virus, human cytomegalovirus, influenza virus, and SARS-CoV-2 (1). This research topic, "Antiviral Monoclonal Antibody Therapies," highlights recent advances in mAb development and their utility against rapidly evolving viral pathogens. Production cost is a major hurdle that needs to be overcome to enable the widespread use of antiviral mAb treatments in low-income communities and countries. Shanmugaraj et al. (2) demonstrate that Nicotiana benthamiana is a powerful costeffective platform for producing mAbs in a scalable and affordable manner. This work describes the first report of SARS-CoV-2-specific mAbs produced in a plant expression system and characterizes their ability to retain neutralization properties in vitro.Another important factor to consider with antiviral mAb therapeutics, is the emergence of escape variants and their recalcitrance to vaccines and mAb treatments. Two studies in this research topic describe different approaches to solving this problem. One highlights the utility of bispecific mAbs, which can be engineered to increase the breadth of mAbs (3). The second delineates a simple and traditional hybridoma approach to mAb development and describes the development of a broadly neutralizing mouse anti-SARS-CoV-2-Spike mAb that neutralizes different SARS-CoV-2 variants(4). Broadly reactive mAbs that target conserved epitopes are attractive targets because they are less likely to result in escape mutations due to the lower fitness of generated mutants.Finally, Kim et al. (5) performed a retrospective multicenter study in South Korea to analyze the effectiveness of Regdanvimab, a SARS-CoV-2-specific mAb, in a hospitalized COVID-19 cohort. They found that compared to the group that received supportive care, patients that received Regdanvimab had reduced progression to severe disease. This was true for the overall study population but not for the patients infected with the SARS-CoV-2 delta variant. This work highlights the potential clinical benefits of antiviral mAb treatments, but also demonstrates that treatment regimens need to be optimized as new variants emerge.With this collection of research articles, we aim to highlight recent advances in the development and production of antiviral mAbs. As emerging and re-emerging viral pathogens continue to cause outbreaks in human populations, a need for effective, flexible, and affordable antiviral treatments is ever-present.

Single-Domain Antibodies As Therapeutics Against Human Viral Diseases

Single-Domain Antibodies as Therapeutics for Respiratory RNA Virus Infections

Next generation single-domain antibodies against respiratory zoonotic RNA viruses

Human Monoclonal Antibodies As Candidate Therapeutics Against Emerging Viruses

Editorial: Antiviral monoclonal antibody therapies

Promises and challenges of single-domain antibodies to control influenza

Potent Human Single-Domain Antibodies Specific for a Novel Prefusion Epitope of Respiratory Syncytial Virus F Glycoprotein

Single-domain antibodies as therapeutics for solid tumor treatment

Potent Germline-Like Monoclonal Antibodies: Rapid Identification of Promising Candidates for Antibody-Based Antiviral Therapy

Fully Human Single-Domain Antibodies Against SARS-CoV-2

Identification of Human Single-Domain Antibodies Against SARS-CoV-2.

[Single-Domain Antibody - Advances in Research and Application].

High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models

Single Domain Antibody application in bacterial infection diagnosis and neutralization

Application Progress of the Single Domain Antibody in Medicine

Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses

VH1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design

Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2

Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2

Single-domain antibodies against SARS-CoV-2 RBD from a two-stage phage screening of universal and focused synthetic libraries

Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics